[{"orgOrder":0,"company":"Hutchmed","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"IMG-004","moa":"BTK","graph1":"Neurology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Hutchmed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"IMG-004","moa":"BTK","graph1":"Neurology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Hutchmed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"IMG-004","moa":"BTK","graph1":"Neurology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Hutchmed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"HMPL-A83","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"HMPL-A83","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"||Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"||Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"||Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Hutchmed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HMPL-295S1","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HMPL-653","moa":"FGFR1\/2\/3","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fanregratinib Tartrate","moa":"||FGFR-1\/FGFR-2\/FGFR-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fanregratinib Tartrate","moa":"FGFR-1\/FGFR-2\/FGFR-3","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Fanregratinib Tartrate","moa":"FGFR-1\/FGFR-2\/FGFR-3","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fanregratinib Tartrate","moa":"FGFR-1\/FGFR-2\/FGFR-3","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"HMPL-453","moa":"Fibroblast growth factor receptor 1 | Fibroblast growth factor receptor 2 | Fibroblast growth factor receptor 3","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"HMPL-453","moa":"Fibroblast growth factor receptor 1 | Fibroblast growth factor receptor 2 | Fibroblast growth factor receptor 3","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"HMPL-453","moa":"Fibroblast growth factor receptor 1 | Fibroblast growth factor receptor 2 | Fibroblast growth factor receptor 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HMPL-453","moa":"Fibroblast growth factor receptor 1 | Fibroblast growth factor receptor 2 | Fibroblast growth factor receptor 3","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Surufatinib","moa":"Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Surufatinib","moa":"||Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ BeOne Medicines","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/ BeOne Medicines"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Surufatinib","moa":"Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Surufatinib","moa":"Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Surufatinib","moa":"Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Surufatinib","moa":"Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Surufatinib","moa":"Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Surufatinib","moa":"Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Surufatinib","moa":"Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Nephrology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Surufatinib","moa":"Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Surufatinib","moa":"Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Surufatinib","moa":"||Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"||Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Surufatinib","moa":"||Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"HengRui","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Surufatinib","moa":"||Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ HengRui","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/ HengRui"},{"orgOrder":0,"company":"Hutchmed","sponsor":"BeOne Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Surufatinib","moa":"||Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Hutchison China MediTech","highestDevelopmentStatusID":"1","companyTruncated":"Hutchmed \/ Hutchison China MediTech"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Savolitinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Savolitinib","moa":"||Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Savolitinib","moa":"||Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0.14000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Baring Private Equity Asia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Savolitinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Baring Private Equity Asia","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Baring Private Equity Asia"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Savolitinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0.14000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Savolitinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Hutchmed","sponsor":"National Healthcare Security Administration","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Savolitinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ National Healthcare Security Administration","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ National Healthcare Security Administration"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Savolitinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Savolitinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Savolitinib","moa":"||Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Savolitinib","moa":"||Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Savolitinib","moa":"||Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Savolitinib","moa":"||Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Savolitinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Savolitinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Savolitinib","moa":"||Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Hutchmed","sponsor":"GL Mountrose Investment Two","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Divestment","leadProduct":"Savolitinib","moa":"||Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ GL Mountrose Investment Two","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ GL Mountrose Investment Two"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Savolitinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Savolitinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Savolitinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Savolitinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Savolitinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Savolitinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Savolitinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Savolitinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Hutchmed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Epizyme","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Epizyme","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Epizyme"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HMPL-306","moa":"IDH-1","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"HMPL-306","moa":"IDH-1","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"HMPL-306","moa":"IDH-1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"HMPL-306","moa":"IDH-1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HMPL-306","moa":"IDH-1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HMPL-306","moa":"IDH-1","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"HMPL-306","moa":"IDH-1","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"HMPL-306","moa":"IDH-1","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"HONG KONG","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Shenqi Sherong Pill","moa":"Immune","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Pill","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"HONG KONG","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Shexiang Baoxin","moa":"Immune","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"HONG KONG","productType":"Antibody, Unconjugated","year":"2024","type":"Licensing Agreement","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hutchmed","amount2":0.46000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.46000000000000002,"dosageForm":"Infusion","sponsorNew":"Hutchmed \/ Inmagene Biopharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Inmagene Biopharmaceuticals"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hutchmed \/ Hutchmed","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hutchmed \/ Hutchmed","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Hutchmed \/ Hutchmed","highestDevelopmentStatusID":"4","companyTruncated":"Hutchmed \/ Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"HONG KONG","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Toripalimab","moa":"Programmed cell death protein 1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Amdizalisib","moa":"PI3-kinase delta (PIK3CD)||PIK3CD","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Amdizalisib","moa":"PIK3CD","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Amdizalisib","moa":"PIK3CD","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pamiparib","moa":"Poly [ADP-ribose] polymerase 2 | Poly [ADP-ribose] polymerase-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Hutchmed","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/ Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Hutchmed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HMPL-415S1","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HMPL-415S1","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hutchmed \/ Hutchmed","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HMPL-760","moa":"Tyrosine-protein kinase BTK (ATK)","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HMPL-760","moa":"Tyrosine-protein kinase BTK (ATK)","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HMPL-760","moa":"Tyrosine-protein kinase BTK (ATK)","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HMPL-506","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HMPL-506","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Beijing Tiantan Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"HONG KONG","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SHPL-49","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hutchmed \/ Beijing Tiantan Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Beijing Tiantan Hospital"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Hutchmed","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Hutchmed","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Hutchmed","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/ Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ BeOne Medicines","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/ BeOne Medicines"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"National Healthcare Security Administration","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ National Healthcare Security Administration","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ National Healthcare Security Administration"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Innovent Biologics"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Eli Lilly"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":1.1299999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":1.1299999999999999,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":1.1299999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":1.1299999999999999,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":1.1299999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":1.1299999999999999,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Innovent Biologics"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Eli Lilly"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Hutchmed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Hutchmed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Eli Lilly"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"HengRui","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ HengRui","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ HengRui"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Hutchmed","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/ Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Covance","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Covance","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Covance"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Nephrology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Hutchmed","amount2":0.92000000000000004,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.92000000000000004,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Inmagene Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Hutchmed \/ Inmagene Biopharmaceuticals"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Shanghai Pharmaceuticals Holding Co.,Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Undisclosed","year":"2025","type":"Divestment","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Hutchmed","amount2":0.60999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.60999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Shanghai Pharmaceuticals Holding Co.,Ltd","highestDevelopmentStatusID":"4","companyTruncated":"Hutchmed \/ Shanghai Pharmaceuticals Holding Co.,Ltd"}]

Find Clinical Drug Pipeline Developments & Deals by Hutchmed

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : Orpathys (savolitinib) in combination with Tagrisso (osimertinib) is approved for the treatment of advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer.

                          Product Name : Orpathys

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 30, 2025

                          Lead Product(s) : Savolitinib,Osimertinib Mesylate

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : HMPL-504 (savolitinib) is an oral, potent, and highly selective MET tyrosine kinase inhibitor, being developed for gastric cancer.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 21, 2025

                          Lead Product(s) : Savolitinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : Tazverik (tazemetostat) is a first-in-class methyltransferase inhibitor of EZH2, which is indicated for the treatment of relapsed or refractory follicular lymphoma.

                          Product Name : Tazverik

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 21, 2025

                          Lead Product(s) : Tazemetostat

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : HMPL-013 (fruquintinib) in combination with IBI308 (sintilimab) is currently being evaluated for the treatment of advanced renal cell carcinoma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 18, 2025

                          Lead Product(s) : Fruquintinib,Sintilimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Recipient : Innovent Biologics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : HMPL-453 (fanregratinib) is a novel, highly selective and potent inhibitor targeting FGFR 1, 2 and 3. It is being evaluated for intrahepatic cholangiocarcinoma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 06, 2025

                          Lead Product(s) : Fanregratinib Tartrate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : Orpathys (savolitinib) is an oral, potent and highly selective MET tyrosine kinase inhibitor. It is approved for MET exon 14 skipping altered NSCLC.

                          Product Name : Orpathys

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 13, 2025

                          Lead Product(s) : Savolitinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : Orpathys is an MET tyrosine kinase inhibitor. Tagrisso is a third-generation, irreversible EGFR TKI. These are being evaluated in combination with EGFR mutation-positive non-small cell lung cancer.

                          Product Name : Orpathys

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 01, 2025

                          Lead Product(s) : Savolitinib,Osimertinib Mesylate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : The proceeds will used to develop its pipeline and strategy including its next-generation ADCs for treating patients suffering from cancers.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : $608.0 million

                          January 01, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Shanghai Pharmaceuticals Holding Co.,Ltd

                          Deal Size : $608.0 million

                          Deal Type : Divestment

                          blank

                          09

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : Orpathys (savolitinib) is an oral, potent and highly selective MET tyrosine kinase inhibitor. It is investigated in combination with osimertinib for EGFR-mutated NSCLC.

                          Product Name : Orpathys

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 11, 2024

                          Lead Product(s) : Savolitinib,Osimertinib Mesylate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : Elunate (fruquintinib) a VEGFR 1/2/3 inhibitor and Tyvyt (sintilimab) has been granted conditional approval in China for the treatment of patients with advanced endometrial cancer.

                          Product Name : Elunate

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 03, 2024

                          Lead Product(s) : Fruquintinib,Sintilimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Innovent Biologics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank